Koteswara Narla, MD
Neurology · Springfield, ILNPI 1326131459
Payments from drug & device makers
What this record shows
This record is dominated by education: $375 of the $615 with a category attached, or 61.0%. 5 manufacturers reported payments, led by AstraZeneca at 32.5% of the total. Reporting peaked in 2024 at $234 and has fallen 79.2% since, to $49 in 2025. That places this record below the midpoint for neurology clinicians in IL, where the typical reported total is $547.
Across 16 payments — averaging $38.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$200
- Teva Pharmaceuticals USA, Inc.$175
- AbbVie$129
- Bristol Myers Squibb$76
- Genentech USA, Inc.$35
What the payments were for
- Food & beverage$24039%
- Education$37561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $200 |
| Teva Pharmaceuticals USA, Inc. | 2 | $175 |
| AbbVie | 6 | $129 |
| Bristol Myers Squibb | 4 | $76 |
| Genentech USA, Inc. | 2 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$100
How this compares
$615 in reported general payments places this provider in the 50th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 16 | $26,613 |
| Pregabalin | 334 | $19,354 |
| Lacosamide | 101 | $18,777 |
| Carbamazepine ErCarbamazepine | 75 | $13,391 |
| Gabapentin | 502 | $9,594 |
| EliquisApixaban | 27 | $8,008 |
| Oxcarbazepine | 155 | $7,638 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 294 | $7,009 |
| Levetiracetam | 308 | $6,735 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 356 | $6,581 |
| Primidone | 362 | $6,315 |
| Memantine Hcl | 173 | $6,106 |
| Levocarnitine | 44 | $4,910 |
| Acetazolamide | 39 | $3,698 |
| Tramadol Hcl | 664 | $3,637 |
Paid to pharmacies, not to this prescriber.
Other neurology in Springfield
- Rodger ElbleSpringfield$47K
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Martha McGrawWinfield$625K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
- Tyler KaplanMaywood$549K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.